Physician profile
Devakumaran J Kumar
NPI 1922196443
$1,198.40
in general payments reported to CMS, 2019-2025
20 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2022: $127 · 2023: $294 · 2024: $303 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $221.50 | 2024 | Apokyn |
| Novartis Pharmaceuticals Corporation | $155.83 | 2019-2025 | |
| Abbvie INC. | $153.13 | 2022-2025 | |
| Celgene Corporation | $150.64 | 2022-2025 | Zeposia |
| Biogen, INC. | $104.98 | 2019 | |
| Lundbeck LLC | $56.68 | 2019-2025 | Vyepti |
| Tg Therapeutics, INC. | $49.89 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $36.06 | 2022-2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $33.37 | 2024-2025 | Rytary, Crexont |
| Genzyme Corporation | $32.60 | 2025 | |
| Sk Life Science, INC. | $31.69 | 2023 | |
| Argenx US, INC. | $29.78 | 2023 | Vyvgart Hytrulo |
| Emd Serono, INC. | $28.24 | 2019 | |
| Supernus Pharmaceuticals, INC. | $26.72 | 2019 | |
| Avanir Pharmaceuticals, INC. | $18.52 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $17.20 | 2022 | |
| Boston Scientific Corporation | $13.79 | 2023 | Watchman Access System |
| Lilly USA, LLC | $12.83 | 2019 | |
| Livanova USA, INC. | $12.57 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devakumaran Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.